Clinical trials: End Stage Kidney Disease (ESKD)
End-Stage Kidney Disease (ESKD), Chronic Kidney Disease (CKD)
Comparing Hemodiafiltration to Conventional Hemodialysis: Effects on Clinical and Biochemical Parameters
Chronic kidney disease may progress to end-stage renal disease, a stage in which the kidneys will no longer be able to adequately remove extra fluid and waste products from the body.
- Trial name
- NCT07662889
- Testing
- Conventional Hemodialysis, Hemodiafiltration
- Where
- Pakistan
- Volunteers
- 64 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Kidney Failure, Chronic, Hyperphosphatemia
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested.
- Trial name
- PHOSPHATE (NCT03573089)
- Testing
- Liberal phosphate target, Intensive phosphate target
- Where
- 126 sites in Australia, Brazil and 7 more
- Volunteers
- 3,600 people
- Sponsor
- The University of Queensland
Arteriovenous Graft
LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft
The study is planned to be conducted at multiple centers, with an intended enrollment of 326 subjects. Protocol-eligible subjects will be randomized in a 1:1 ratio to either the investigational group or the control group.
- Trial name
- NCT07773051
- Testing
- LineMatrix® Biological Vascular Graft, GORE-INTERING®
- Where
- 12 sites in China
- Volunteers
- 326 people
- Sponsor
- Longhua Hospital
Intradialytic Hypertension, End Stage Kidney Disease
Effect of Low Versus Standard Dialysate Sodium on 48h Ambulatory BP in Patients With Intradialytic Hypertension
Intradialytic hypertension (IDH) is a well-recognized and established complication of hemodialysis that affects an estimated 10-15% of the dialysis population and is associated with an increased risk for cardiovascular adverse…
- Trial name
- NCT05430438
- Testing
- dialysis with low dialysate sodium concentration, dialysis with standard dialysate sodium concentration
- Where
- 4 sites in Greece, Slovenia
- Volunteers
- 30 people
- Sponsor
- Aristotle University Of Thessaloniki
End-Stage Kidney Disease (ESKD), Hemodialysis
Effects of Intradialytic Nutrition on Dialysis Adequacy and Fatigue
This randomized, two-period, two-sequence crossover trial aims to evaluate the effects of intradialytic nutrition on dialysis adequacy, intradialytic hemodynamic parameters, and fatigue in adults receiving maintenance…
- Trial name
- NCT07687498
- Testing
- Standardized Intradialytic Nutrition
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Mersin University
End-Stage Kidney Disease (ESKD), Cardiovascular Disease
Cardiovascular Mortality Prediction in Maintenance Hemodialysis Patients
This prospective, single-center observational cohort study evaluates cardiovascular mortality risk in adults receiving maintenance hemodialysis.
- Conditions
- End-Stage Kidney Disease (ESKD), Cardiovascular Disease, Secondary Hyperparathyroidism (SHPT)
- Trial name
- NCT07769190
- Testing
- One-Year Serum Phosphate Target Achievement Rate, Parathyroidectomy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Huashan Hospital
End Stage Kidney Disease (ESKD)
Acupuncture for Symptom Burden and Quality of Life in Patients With End-Stage Kidney Disease
Patients with end-stage kidney disease (ESKD) undergoing hemodialysis or peritoneal dialysis experience a high burden of symptoms, including fatigue, pain, pruritus, muscle cramps, and sleep disturbances, which substantially…
- Trial name
- Acup-ESKD (NCT07887607)
- Testing
- Acupuncture
- Where
- Greece
- Volunteers
- 160 people
- Sponsor
- University General Hospital of Heraklion
Kidney Disease, Chronic Kidney Disease (Stages 4 and 5)
The Adaptive Platform Trial for Kidney Disease
Background: Randomized clinical trials (RCTs) are essential for evaluating intervention effects but are often challenged by regulatory and logistical burdens, high costs, and extended timelines.
- Conditions
- Kidney Disease, Chronic Kidney Disease (Stages 4 and 5), End-Stage Kidney Disease (ESKD), Dialysis
- Trial name
- APT-KIDNEY (NCT07595952)
- Testing
- APT-KIDNEY platform participation
- Volunteers
- 5,000 people
- Sponsor
- Nicholas Carlson
End-stage Kidney Disease, Kidney Disease, Chronic
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients.
- Conditions
- End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic
- Trial name
- NCT05614115
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Utah
End Stage Kidney Disease (ESKD), Hypertension (HTN)
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis.
- Conditions
- End Stage Kidney Disease (ESKD), Hypertension (HTN), Peritoneal Dialysis (PD)
- Trial name
- GOAL-BP (NCT07910773)
- Testing
- Target systolic blood pressure <120 mmHg., Target systolic blood pressure <140 mmHg
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
End Stage Kidney Disease (ESKD), Hyperglycaemia
Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring
This study will evaluate whether Continuous Glucose Monitoring (CGM) can identify previously unrecognized diabetes and clinically significant hyperglycemia in adults with end-stage kidney disease (ESKD) receiving hemodialysis who…
- Conditions
- End Stage Kidney Disease (ESKD), Hyperglycaemia, Diabetes
- Trial name
- NCT07880795
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Emory University
Pulmonary Hypertension
Idiopathic Pre-capillary Pulmonary Hypertension in ESKD Patients
This study investigates the prevalence and prognosis of idiopathic pre-capillary pulmonary hypertension (PH) in patients with end-stage kidney disease (ESKD).
- Trial name
- NCT02743091
- Volunteers
- 1,988 people
- Sponsor
- Toujinkai Hospital
End Stage Renal Disease on Dialysis
Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD
Fight Fatigue is evaluating the feasibility and acceptability of a combined progressive muscle relaxation and walking intervention to reduce fatigue for adults with end-stage kidney disease receiving in-center hemodialysis.
- Trial name
- NCT07014111
- Testing
- Fight Fatigue, Attention Control
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois Chicago
End Stage Kidney Disease (ESKD), Hemodialysis
Medium Cut-Off and High-Flux Membranes on Mineral and Bone Metabolism in Hemodialysis Patients
This study aims to compare the effects of medium cut-off (MCO) and high-flux hemodialysis membranes on mineral and bone metabolism biomarkers in patients receiving maintenance hemodialysis.
- Conditions
- End Stage Kidney Disease (ESKD), Hemodialysis, Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- MBD-HD (NCT07685223)
- Testing
- Medium Cut-Off Hemodialysis Membrane, High-Flux Hemodialysis Membrane
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Gazi University
Kidney Failure, Chronic, Heart Failure
Empagliflozin in ESKD - A Feasibility Study
The aim of this study is to learn about the safety of empagliflozin in dialysis patients as a preparation for a future large clinical trial.
- Trial name
- NCT05687058
- Testing
- Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Mississippi Medical Center
End Stage Kidney Disease (ESKD), Hemodialysis
Liberalizing Potassium Restrictions in Patients Receiving Hemodialysis
People with end-stage kidney disease who receive hemodialysis are often told to strictly limit foods high in potassium, such as fruits, vegetables, legumes, nuts, and whole grains.
- Conditions
- End Stage Kidney Disease (ESKD), Hemodialysis, Diet Intervention, Hyperkalemia
- Trial name
- LIBERATE-K HD (NCT07772856)
- Testing
- Liberalized Potassium Diet, Low Potassium Diet
- Where
- Canada
- Volunteers
- 148 people
- Sponsor
- University of Ontario Institute of Technology
Perioperative Management, End Stage Kidney Disease (ESRD)
Preoperative Hemodialysis Timing in Patients With End-Stage Kidney Disease: The POD-ESKD Pilot Trial
The goal of this clinical trial is to evaluate the feasibility of two different preoperative hemodialysis schedules for people with end-stage kidney disease (ESKD) who undergo surgical procedures.
- Conditions
- Perioperative Management, End Stage Kidney Disease (ESRD), Hemodialysis
- Trial name
- POD-ESKD (NCT07339202)
- Testing
- Same-Day Hemodialysis, No Same-Day Hemodialysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate.
- Conditions
- Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
- Trial name
- RESPOND-2 (NCT06933472)
- Testing
- AP301, AP301 Low Dose
- Where
- 42 sites in United States, China
- Volunteers
- 264 people
- Sponsor
- Alebund Pharmaceuticals
Secondary Hyperparathyroidism, End-stage Kidney Disease
The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD
Patients with end-stage kidney disease (ESKD) have an increased risk of cardiovascular mortality. High parathyroid hormone (PTH) from secondary hyperparathyroidism leads to increased efflux of phosphate and calcium from bone…
- Trial name
- CaT50HD (NCT06398002)
- Testing
- Dialysate calcium 1.50 mmol/L
- Volunteers
- 48 people
- Sponsor
- Iain Bressendorff
End-Stage Kidney Disease (ESKD)
Virtual Reality-Guided Imagery in Hemodialysis Patients ( VRGI-HD )
This randomized controlled trial aims to evaluate the effect of virtual reality guided imagery on selected health outcomes among adult patients receiving maintenance hemodialysis.
- Trial name
- NCT07867444
- Testing
- virtual reality-guided imagery (VRGI)
- Volunteers
- 80 people
- Sponsor
- Islamic University of Najaf